Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Rush Md Anderson Cancer Center
Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
- Loyola University Medical Center
Maywood, Illinois, United States
- Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
- Rush Md Anderson Cancer Center at Rush Oak Park
Oak Park, Illinois, United States
- University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
- Ui Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, United States
- Iowa Methodist Medical Center
Des Moines, Iowa, United States
- Ui Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, United States
- University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- East Jefferson General Hospital
Metairie, Louisiana, United States
- Lsu Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana, United States
- Tulane University School of Medicine
New Orleans, Louisiana, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Umass Memorial Medical Center - University Campus
Worcester, Massachusetts, United States
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, United States
- Minnesota Oncology - Burnsville
Burnsville, Minnesota, United States
- Minnesota Oncology Hematology Pa-Maplewood
Maplewood, Minnesota, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- Missouri Baptist Medical Center
St Louis, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Nyp/weill Cornell Medical Center
New York, New York, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Upmc-Shadyside Hospital
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Jul 2020
- Primary completion
- 1 Oct 2026
- Completion
- 1 Oct 2026
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 134
- Registry id
- NCT04071223
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.